Chinook Therapeutics Inc KDNY
Muddy Waters is short Chinook (KDNY): lead drug atrasentan is inefficacious, harmful, and blocked by sparsentan's IgAN orphan-drug exclusivity — FDA approval is highly unlikely.
Thesis
Muddy Waters is short Chinook Therapeutics (NASDAQ:KDNY) on the thesis that its lead candidate atrasentan will not win FDA approval. SONAR Phase 3 data, originally run by AbbVie, shows atrasentan produces no statistically-significant effect on end-stage renal disease (p=0.06), while UACR, systolic blood pressure and other surrogate biomarkers snap back to placebo within weeks of drug cessation — consistent with a hemodynamic, not structural, renal effect. Patients on atrasentan died at numerically higher rates than placebo and suffered elevated heart failure (136 vs 93 events) and anemia (18.5% vs 10.3%). Both AbbVie and Chinook appear to have manipulated graphs, composite endpoints, and stroke numbers to obscure these results. Critically, rival Travere Therapeutics' sparsentan already holds exclusive FDA orphan-drug approval for IgA nephropathy through February 2030, leaving atrasentan without a viable path to market.
SCQA
Chinook Therapeutics is a clinical-stage biotech whose valuation rests almost entirely on atrasentan, an endothelin-receptor antagonist in-licensed from AbbVie, now in the Phase 3 ALIGN trial for IgA nephropathy.
AbbVie's earlier SONAR Phase 3 trial showed atrasentan is inefficacious for CKD — no statistically-significant ESRD benefit — and carries elevated mortality, heart failure, and anemia risks; both companies appear to have manipulated graphs and composite endpoints to conceal these findings.
Investors should recognize that the FDA is unlikely to approve atrasentan, and that Travere's sparsentan — already holding exclusive orphan-drug approval for IgAN through 2030 — structurally blocks Chinook's only commercial path even if efficacy and safety were acceptable.
If atrasentan fails approval or is blocked by sparsentan's exclusivity, Chinook's single-asset pipeline collapses, making KDNY equity substantially overvalued at current levels and vindicating Muddy Waters' short position.
The three reasons
- 1
SONAR trial shows atrasentan fails to slow ESRD (p=0.06); biomarker gains vanish within weeks of cessation
- 2
Atrasentan raises mortality, heart failure (136 vs 93) and anemia (18.5% vs 10.3%) versus placebo
- 3
Travere's sparsentan holds exclusive FDA orphan drug approval for IgAN through February 2030
Primary demands
- Reject atrasentan's path to FDA approval: drug is inefficacious for CKD
- Acknowledge elevated mortality, heart failure, and anemia risks obscured by AbbVie/Chinook
- Recognize sparsentan's exclusive orphan-drug approval blocks atrasentan from IgAN market through 2030
KPIs cited
Pattern membership
Where this document fits across the library's 12 rhetorical / structural patterns.
Precedents cited
- Avosentan (discontinued for heart failure risk)
- Sparsentan PROTECT/DUET studies (Travere)
- AbbVie SONAR trial closure (2018)
Notable slides (6)
Notes
Long-form Muddy Waters research note (35 numbered pages + disclaimer cover), not a slide deck. Word-processor style with extensive footnotes (>150 citations to clinical literature and FDA/clinicaltrials.gov data). Combines clinical-trial forensics (re-reading SONAR, RADAR, AFFINITY data to find concealed mortality, anemia, heart failure, and graph-distortion evidence) with a regulatory-blocking argument (sparsentan's orphan-drug exclusivity). Villain posture is directed primarily at the underlying drug development and AbbVie's conduct; Chinook is implicated via its reporting and conference presentations. No stake disclosed beyond the standard MW short-interest disclaimer. No explicit price target. Most visuals are reproduced third-party clinical charts, not original visx-grade artwork — hence low visual_craft_interest.